Gross margin pressure from rising API costs
Geopolitical tensions may increase API prices, impacting gross margins. Management noted indirect impact but expects to manage within 80% gross margin band.
CORONAREMEDIES / Q4-FY26 / risks
Keep the risk register visible.
Corona Remedies · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Integration and margin dilution from Wokadin acquisition
Wokadin acquisition may cause ~400bps gross margin correction in first year due to NLEM portfolio. Management expects 25% revenue growth but margin recovery uncertain.
Execution risk in new divisions and biosimilars
New infertility and multispecialty divisions, plus biosimilar launches, require ramp-up time. PCPM for new hires takes 3+ years to mature.